Occupational Dermatoses in 101 Polish Private Farmers
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, home or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
The question behind this paper
This review looks at private farming and occupational-disease recognition. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 101 compensated occupational-dermatosis cases among Polish private farmers: 63 women and 38 men |
| Design | Retrospective compensation-register analysis |
| Timepoint | 1991 through 1999 |
| Key result | Allergic contact dermatitis accounted for 86%, infections 10%, irritant dermatitis 3% and urticaria 2%. Plant dusts were listed in 38%, animal allergens 36%, metals 29%, pesticides 18% and rubber chemicals 15%. |
How to interpret the result
The very low registered incidence and rapid rise are more consistent with underrecognition and system change than a sudden biological shift. Exposure percentages overlap and are not causal fractions.
Important limitation: The study counted recognized compensated cases rather than all disease, multiple exposures could be assigned, and rising incidence likely reflected detection and compensation changes.
Questionnaires, examinations, sensors, patch tests and administrative records answer different questions. A screening or monitoring result can guide the next step, but it does not diagnose the cause of one person’s rash. An association can identify a pattern worth investigating without proving that a single task, material or personal factor caused every event.
Questions a worker, family or clinician can ask next
- What exactly was measured: reported symptoms, visible signs, allergy, work loss or quality of life?
- Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
- Did the study compare groups or follow change over time, and what factors could still explain the difference?
- Would clinician examination, occupational-health review or clinician-directed testing change the practical plan?
- What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 12768615
- Authoritative guidance relevant to this topic
- American Academy of Dermatology: eczema skin-care guidance
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.